OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Want to cut your energy bills? Here’s how five experts are doing it 
WATERTOWN, Mass., March 03, 2017 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on March 8, 2017, and will host a conference call on Wednesday, March 8, 2017 at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
The call can be accessed by dialing (844) 831-4023 (U.S. and Canada) or (731) 256-5215 (international) and entering passcode 82825167. To access the live audio webcast, or the subsequent archived recording, visit the "Investor Relations - Events & Presentations" section of the Tetraphase website at www.tphase.com. The webcast will be recorded and available for replay on the Tetraphase website for 30 days following the call.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected]
